Guzip Biomarkers Corporation
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
Guzip’s flagship products include MPap® and RitaPap®, both of which use methylation-specific qPCR to detect methylation status of key genes; MPap uses cervical scrape samples, while RitaPap uses tampon-collected samples.
They also develop a MUrine test (
They also develop a MUrine test (
Founded Year
2018
Unified Business No.
50859246
Status
Active
Number of Employees
10
Total Paid-in
Capital
38,723,910 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Acquired(2025)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Guzip Biomarkers Corporation, founded in 2018 as a spin‑out from Taipei Medical University, is a research‑driven biotech company specializing in epigenetics and DNA methylation.
Their mission is to develop novel methylation‑based biomarkers for clinical applications, particularly in women’s health.
Their mission is to develop novel methylation‑based biomarkers for clinical applications, particularly in women’s health.
Corporate Video
